- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04479722
Using Left Atrium Appendage Closure in NVAF Patients With High Risk of Ischemic Stroke (SAFE-PROTECT)
Safety And EFficacy of Using LEft Atrium APpendage Closure in Nonvalvular AtRial FibrillatiOn PatienTs With High Risk of ischEmiC sTroke -- A Prospective Multicenter Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
SAFE-PROTECT trial is composed of Roll-in group, small-size group and RCT group. This trial is planned to conduct in about 20 sites from China.
Roll-in group plans to enroll at most 3 subjects each site to implant experimental device for exploration and observation.
RCT group plans to enroll no less than 210 subjects who meet the inclusion/exclusion criteria, and 1:1 randomly allocated to experimental arm or comparator arm.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ben He, Prof.
- Phone Number: 0086-13701733685
- Email: heben@medmail.com.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China
- Shanghai Chest Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Non valvular atrial fibrillation subjects aged ≥18 and ≤80;
High risk of ischemic stroke: CHA2DS2VASc score ≥ 2 ( ≥ 3 for female) together with any of the following circumstances:
- With a recorded history (happened earlier than 6 months from now) of bleeding (including gingival/nasal/oral bleeding, skin &soft tissue bleeding, gastrointestinal bleeding, urinary tract bleeding, cerebral haemorrhage, etc.) or bleeding tendency;
- Intolerance or rejection of long-term anti-coagulation therapy;
- Suffering stroke or embolism despite routine anti-coagulation therapy;
- With a predicting HAS-BLED score ≥3.
- Subjects (or his/her legal representatives) are able to understand the study objectives, willing to cooperate with procedure and follow-up. Subjects who voluntarily participate in this trial and have signed the written informed consent form.
Exclusion Criteria:
- Subjects with atrial fibrillation (AF) caused by rheumatic valvular disease, moderate to severe mitral stenosis, severe mitral regurgitation, severe aortic valve disease or severe left ventricular outflow tract obstruction with pressure difference greater than 40mmHg;
- Suffering with other disease(s) requiring long-term oral anticoagulation treatment;
- Initial untreated AF, or secondary AF with clear cause (such as hyperthyroid heart disease);
- Intracardiac thrombus (including left and/or right atrium) found or persisted;
- Suffered with myocardial infarction within 3 months;
- History of previous atrial septum repair operation or Atrial Septal Occluder implantation;
- History of previous heart valve (mechanical valve) replacement operation;
- Subjects undergoing heart transplant operation;
- Subjects with symptomatic carotid artery disease (such as carotid stenosis > 50%) or subjects with vulnerable carotid artery plaque.
- Suffered with ischemic stroke or TIA recently (within 30 days);
- Known complex active atherosclerotic plaque(s) in the descending aorta or aortic arch;
- Severe heart failure (NYHA Grade Ⅳ);
- The investigator assessed that there were abnormal result(s) with clinical significance in the routine blood test of subjects;
- Severe renal abnormal: serum creatinine >250μmol/l; or on dialysis;
- Allergic or contraindicated to aspirin, clopidogrel, heparin, contrast agent, and nitinol alloy;
- Subjects who are scheduled to receive operation within 1 year after procedure, and need to stop anti-thrombotic therapy;
- Pregnant or breast-feeding subjects, or subjects who plan to have a child within 1 year after procedure;
- Subjects with a life expectancy less than 12 months;
- Subjects who are participating in another investigational drug or device clinical trial in which the primary endpoint is still not reached before enrolment;
- Subjects have other reasons that cannot maintain 2 months anticoagulation or 6 months dual antiplatelet therapy;
- Subjects with poor compliance (judged by investigator) or cannot complete the study according to the protocol due to other reasons;
- Subjects who are unsuitable to receive LAA occlusion treatment (judged by investigator).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Microport CardioAdvance LAAC system
Subject implant Microport CardioAdvance LAAC system to occlude LAA through percutaneous intervention.
|
Implant LAAC system in LAA through percutaneous intervention
|
Active Comparator: Watchman LAAC system
Subject implant Watchman LAAC system to occlude LAA through percutaneous intervention.
|
Implant LAAC system in LAA through percutaneous intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical success
Time Frame: 12-month
|
Freedom from ischemic stroke, hemorrhagic stroke, systemic embolism, cardiovascular death and unexplained death
|
12-month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LAA occlusion success
Time Frame: 12-month
|
TEE examination showing that the residual shunt < 5mm jet width or complete occlusion of LAA
|
12-month
|
Collaborators and Investigators
Investigators
- Study Chair: Ming Zheng, Prof., MicroPort Orthopedics Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAFE-PROTECT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data that underlie the results reported in the article, after deidentification (text, tables, figures, and appendices) will be shared. Additionally, study protocol will be available. The data will become available for the beginning 3 months and ending 5 years following article publication.
If the data sharing plan changes after registration, this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on Left atrial appendage closure procedure
-
Laminar, Inc.Active, not recruitingAtrial FibrillationGeorgia, Paraguay
-
University of TurkuHelsinki University Central Hospital; Kuopio University Hospital; St. Antonius... and other collaboratorsRecruitingAortic StenosisFinland, Netherlands
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital of Nanchang University; LanZhou University; The... and other collaboratorsCompletedNon-valvular Atrial FibrillationChina
-
University Hospital Inselspital, BerneActive, not recruitingLeft Atrial Appendage ClosureBelgium, France, Italy, Switzerland
-
Abbott Medical DevicesActive, not recruitingStrokeUnited States, Denmark, Germany, Australia, Spain, Canada, Czechia, Italy, Netherlands, Portugal, Switzerland
-
Laminar, Inc.Recruiting
-
Conformal Medical, IncCompleted
-
Abbott Medical DevicesRecruiting
-
Charles University, Czech RepublicBrno University Hospital; General Teaching Hospital, PragueRecruitingAtrial Fibrillation | Left Atrial Appendage ClosureCzechia
-
Conformal Medical, IncYale Cardiovascular Research GroupActive, not recruiting